Trade Summary

3 days ago, Yea Christopher, serving as CHIEF DEVELOPMENT OFFICER at KalVista Pharmaceuticals, Inc. (KALV), sold 33,800 shares at $26.78 per share, for a total transaction value of $905,224.84. Following this transaction, Yea Christopher now holds 229,918 shares of KALV.

This sale represents a 12.82% decrease in Yea Christopher's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Wednesday, May 27, 2026 and publicly disclosed via SEC Form 4 filing on Friday, May 29, 2026 at 4:05 PM ET, 2 days after the trade was made.

KalVista Pharmaceuticals, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.